Cryptococcal Meningitis: Epidemiology and Therapeutic Options

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Specialty Public Health

Date 2014 May 30

PMID 24872723

Citations 115

Authors

Derek J Sloan

Victoria Parris

Affiliations

Soon will be listed here.

Abstract

Cryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three phases: induction, consolidation, and maintenance. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine), which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to effective treatment is urgently required to improve outcomes. For human immunodeficiency virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and appropriately timed introduction of antiretroviral therapy are important.

Citing Articles

Review of the aetiologies of central nervous system infections in Vietnam.

Brindle H, Choisy M, Christley R, French N, Griffiths M, Thai P Front Public Health. 2025; 12:1396915.

PMID: 39959908 PMC: 11825750. DOI: 10.3389/fpubh.2024.1396915.

Cryptococcus neoformans Periprosthetic Joint Infection in the Setting of Revision Shoulder Arthroplasty: A Case Report.

Gabriel S, Boin M Cureus. 2024; 16(10):e71253.

PMID: 39525101 PMC: 11550565. DOI: 10.7759/cureus.71253.

Diagnostic Performances of an in-House Immunochromatography Test Based on the Monoclonal Antibody 18B7 to Glucuronoxylomannan for Clinical Suspected Cryptococcosis: a Large-Scale Prototype Evaluation in Northern Thailand.

Pruksaphon K, Amsri A, Thammasit P, Nosanchuk J, Aiumurai P, Youngchim S Mycopathologia. 2024; 189(5):75.

PMID: 39120647 PMC: 11517805. DOI: 10.1007/s11046-024-00882-x.

Intracranial granulomatous inflammation caused by cryptococcal infection: a case study and literature analysis.

Deng X, Xiao X Quant Imaging Med Surg. 2024; 14(7):5248-5254.

PMID: 39022242 PMC: 11250357. DOI: 10.21037/qims-23-1860.

Design of an epitope-based peptide vaccine against Cryptococcus neoformans.

Omer I, Khalil I, Abdalmumin A, Molefe P, Sabeel S, Farh I FEBS Open Bio. 2024; 14(9):1471-1489.

PMID: 39020466 PMC: 11492362. DOI: 10.1002/2211-5463.13858.

References

Kambugu A, Meya D, Rhein J, OBrien M, Janoff E, Ronald A . Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46(11):1694-701. PMC: 2593910. DOI: 10.1086/587667. View

Rugemalila J, Maro V, Kapanda G, Ndaro A, Jarvis J . Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. Trop Med Int Health. 2013; 18(9):1075-1079. DOI: 10.1111/tmi.12157. View

Antinori S . New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS. 2013; 2013:471363. PMC: 3767198. DOI: 10.1155/2013/471363. View

Seaton R, Verma N, Naraqi S, Wembri J, Warrell D . The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg. 1997; 91(1):50-2. DOI: 10.1016/s0035-9203(97)90393-x. View

Seaton R . The management of cryptococcal meningitis in Papua New Guinea. P N G Med J. 1996; 39(1):67-73. View

Ellis D . Cryptococcus neoformans var. gattii in Australia. J Clin Microbiol. 1987; 25(2):430-1. PMC: 265916. DOI: 10.1128/jcm.25.2.430-431.1987. View

Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A . Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011; 11(12):933-41. PMC: 4856956. DOI: 10.1016/S1473-3099(11)70245-6. View

Dromer F, Mathoulin S, DuPont B, Laporte A . Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis. 1996; 23(1):82-90. DOI: 10.1093/clinids/23.1.82. View

French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M . Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002; 16(7):1031-8. DOI: 10.1097/00002030-200205030-00009. View

10.

Singh N, Lortholary O, Alexander B, Gupta K, John G, Pursell K . An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005; 40(12):1756-61. DOI: 10.1086/430606. View

11.

Speed B, Dunt D . Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995; 21(1):28-34; discussion 35-6. DOI: 10.1093/clinids/21.1.28. View

12.

Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A . Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008; 47(12):1556-61. DOI: 10.1086/593194. View

13.

Milefchik E, Leal M, Haubrich R, Bozzette S, Tilles J, Leedom J . Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008; 46(4):393-5. DOI: 10.1080/13693780701851695. View

14.

French M . HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2008; 48(1):101-7. DOI: 10.1086/595006. View

15.

Alemu A, Kempker R, Tenna A, Smitson C, Berhe N, Fekade D . High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One. 2013; 8(3):e58377. PMC: 3587601. DOI: 10.1371/journal.pone.0058377. View

16.

van der Horst C, Saag M, Cloud G, Hamill R, Graybill J, Sobel J . Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997; 337(1):15-21. DOI: 10.1056/NEJM199707033370103. View

17.

Singh N, Alexander B, Lortholary O, Dromer F, Gupta K, John G . Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007; 195(5):756-64. PMC: 2746485. DOI: 10.1086/511438. View

18.

Brizendine K, Baddley J, Pappas P . Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013; 8(3):e60431. PMC: 3608592. DOI: 10.1371/journal.pone.0060431. View

19.

Jarvis J, Lawn S, Vogt M, Bangani N, Wood R, Harrison T . Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009; 48(7):856-62. PMC: 2875173. DOI: 10.1086/597262. View

20.

Jackson A, van der Horst C . New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep. 2012; 9(3):267-77. DOI: 10.1007/s11904-012-0127-7. View